Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01273922 | Safety and Immunogenicity Study of a Recombinant Protein Vaccine (NDV-3) Against S.Aureus and Candida | PHASE1 | COMPLETED | 40 | — | — | Jan 1, 2011 | Dec 1, 2011 | May 22, 2012 | 1 | United States |
Clinical evaluations and safety laboratories
| Arm | Type | Description |
|---|---|---|
| Low Dose NDV-3 investigational vaccine | PLACEBO_COMPARATOR | 15 subjects will receive vaccine and 5 subjects will receive placebo. |
| High Dose NDV-3 investigational vaccine | PLACEBO_COMPARATOR | 15 subjects will receive vaccine and 5 subjects will receive placebo |
| Name | Type | Description |
|---|---|---|
| NDV-3 investigational vaccine | BIOLOGICAL | Two doses of vaccine 6 months apart or placebo(only one dose at Time 0) administered intramuscularly |
Inclusion Criteria: 1. Informed of the nature of the study and have agreed to and are able to read, review, and sign the informed consent document prior to screening. The informed consent document will be written in English, therefore the subject must have the ability to read and communicate in Eng...